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Exosomes are secretedmembrane vesicles that have been proposed as an effectivemeans
to detect a variety of disease states, including cancer.The properties of exosomes, includ-
ing stability in biological ﬂuids, allow for their efﬁcient isolation and make them an ideal
vehicle for studies on early disease detection and evaluation. Much data has been col-
lected over recent years regarding the messenger RNA, microRNA, and protein contents
of exosomes. In addition, many studies have described the functional role that exosomes
play in disease initiation and progression. Tumor cells have been shown to secrete exo-
somes, often in increased amounts compared to normal cells, and these exosomes can
carry the genomic and proteomic signatures characteristic of the tumor cells from which
they were derived.While these unique signatures make exosomes ideal for cancer detec-
tion, exosomes derived from cancer cells have also been shown to play a functional role in
cancer progression. Here, we review the unique genomic and proteomic contents of exo-
somes originating from cancer cells as well as their functional effects to promote tumor
progression.
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BACKGROUND
Exosomes are small membrane vesicles ranging from 40 to 100 nm
in size that are formed within multivesicular bodies (MVB) and
secreted upon fusion of the MVB with the plasma membrane
(Denzer et al., 2000). Exosomes were ﬁrst described in 1987 when
Johnstone et al. (1987) noted that vesicles shed from cultured
monolayer cells retained enzymatic activity reminiscent of the
parent cells. It was later determined that exosomes are remnants
of the endocytic pathway following endosomal sorting of com-
ponents that are not degraded by lysosomes. These vesicles are
then released from the cell in the form of exosomes. Thus, exo-
somes were ﬁrst thought of as a way of disposing unnecessary
membrane proteins, especially during reticulocyte maturation
(Johnstone et al., 1989, 1991; Johnstone, 1992). It is now known
that this is not entirely the case and exosomes can have signiﬁ-
cant biological roles (Thery et al., 2002; Johnstone, 2006; Thery,
2011; Yang and Robbins, 2011). It is worth noting that some con-
fusion exists regarding the terms: “exosome” and “microvesicle.”
Most researchers discriminate between the twomostly on the basis
of size, with exosomes falling in the range of 40–100 nm and
microvesicles in the rangeof 100–200 nm. Someof the studies cited
in this review will use these terms with more stringent require-
ments while others use the terms interchangeably. Still others use
only the term “microvesicle” as a general term to include both
types of secreted vesicles. Since exosome/microvesicle research is
still a ﬂedgling ﬁeld, these deﬁnitions may change over time to
become more stringent or may include additional parameters to
deﬁne each type of vesicle.
Exosome membranes are enriched in cholesterol, sphin-
gomyelin, and ceramide (Simpson et al., 2008) as well as lipid raft
associated proteins (de Gassart et al., 2003). These components
allow exosomes to be highly stable and they can thus be collected
from numerous bodily ﬂuids (Keller et al., 2011) including blood
(Li et al., 2008), urine (Gonzales et al., 2010), breast milk (Zhou
et al., 2012), ascites (Navabi et al., 2005), and saliva (Ogawa et al.,
2008). Once these ﬂuids have been collected, exosomes can be eas-
ily isolated using differential ultracentrifugation in order to ﬁrst
remove large cells and debris and then pellet the exosomes. The
ubiquitous nature of exosomes in bodily ﬂuids makes them ideal
for use in diagnostic biomarker studies. In addition, studies have
shown that exosomes can also have a functional role in human
biology (Figure 1).
Exosomes are secreted by two different mechanisms, consti-
tutive release via the Trans-Golgi Network and inducible release
(Record et al., 2011). It is often noted that exosome concentra-
tions are increased in cancer patients compared to normal controls
(Taylor and Gercel-Taylor, 2008; Logozzi et al., 2009), though the
reason for this is not fully understood. One study noted that the
tumor suppressor protein p53 induces activation of tumor sup-
pressor activated pathway-6 (TSAP6) following DNA damage (Yu
et al., 2006). This same study found that over-expression of TSAP6
upregulates exosome production, even in the absence of a func-
tional p53 protein. It is possible that cancer cells release prodigious
amounts of exosomes due to high TSAP6, though this link has not
yet been made. Another possibility is general upregulation of exo-
some secretion due to RabGTPases. The Rab family of proteins are
often mutated (constitutively active) or over-expressed in cancer
cells. It is known that several members of the Rab GTPase family
can affect exosome secretion via the Trans-Golgi Network (Pon-
nambalamandBaldwin, 2003) or by inducible vesicular trafﬁcking
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FIGURE 1 | Schematic of exosome secretion in a cancer cell model.
Exosomes are secreted via a constitutive pathway involving theTrans-Golgi
Network and/or inducible pathways, which can be activated by a
p53-mediated response to DNA damage or Rab GTPases. Characteristic
protein and RNA components are shown for a canonical exosome.
Exosomes released from cancer cells can be taken up by neighboring cells
and are capable of inducing pathways involved in cancer initiation and
progression.
(Loomis et al., 2006;Ostrowski et al., 2010). These factors and their
role in exosome secretion are depicted in Figure 1.
Canonical exosomes contain lipids, proteins, microRNA
(miRNA), andmessenger RNA (mRNA). These components, after
being secreted by a source cell, can be taken up by target cells
wherein the proteins may affect cellular signaling and the miRNA
and mRNA could modulate gene transcription and translation.
Early functional studies focused on the role of exosomes in reticu-
locytematuration and immune cell function. Since that time, it has
been suggested that exosomes also play an important role in certain
diseases such asAlzheimer’s disease (Rajendran et al., 2006),where
beta-amyloid peptides are secreted from cells via exosomes. It is
believed that these exosomes contribute to the pathogenesis of the
disease by spreading Alzheimer’s-related proteins to surrounding
cells. Additionally, the role of exosomes in immune system func-
tions is also well documented (Li et al., 2006; Bobrie et al., 2011;
Chaput and Thery, 2011).
Rather than being a random sampling of intracellular com-
ponents, exosomes contain very speciﬁc types of proteins. Since
exosomes form by budding of the plasma membrane, these pro-
teins are generally cell surface receptors and components of the
endocytic pathway. However, they are also known to contain select
cytosolic proteins, such as heat shock proteins (Mathew et al.,
1995; Clayton and Tabi, 2005). Many of the proteins, miRNA, and
mRNA found in exosomes have a role in cancer development and
progression (Table 1). In terms of the function of cancer cell-
derived exosomes, there is conﬂicting evidence in the literature
as studies have indicated that exosomes derived from cancer cells
can have both anti-tumorigenic and pro-tumorigenic properties
(Yang and Robbins, 2011). Here, we will review the genomic and
proteomic data from cancer cell-derived exosomes. Furthermore,
we examine how these exosomes could affect cancer progres-
sion and how they might be utilized for cancer diagnosis and
treatment.
FUNCTION OF TUMOR-DERIVED EXOSOMES
Although exosomes derived from tumor cells have been shown
to have anti-tumorigenic properties such as inducing tumor cell
apoptosis (Ristorcelli et al., 2008) and enhancing anti-tumor
immunity (Zhang et al., 2010), there is increased evidence that
these exosomes could play a more important role in tumor pro-
gression (Yang and Robbins, 2011). It is not often that a cancer
patient dies from a lone primary tumor; it is generally the dissem-
ination of tumor cells throughout the body and their unchecked
proliferation that interferes with organ function and causes the
patient to succumb to the disease. In order for this to happen,
cells derived from the primary tumor must accumulate muta-
tions in numerous genes that affect cellular functions, such as
growth, apoptosis, migration, and angiogenesis (Hanahan and
Weinberg, 2000). Because exosomes carry genomic and proteomic
materials known tomediate these hallmarks of cancer, it is hypoth-
esized that exosomes secreted by tumor cells have a role in the
growth and dissemination of tumor cells. Indeed, many studies
have demonstrated such potential in tumor-derived exosomes.
One of the hallmark properties of tumorigenicity is the abil-
ity of cells to form colonies on soft agar, which is indicative
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of anchorage-independent growth (AIG). Ochieng et al. (2009)
demonstrated that exosomes isolated from fetal bovine serum
(a common supplement in cell culture media) were capable of
inducing AIG in breast cancer cells. When cells were grown using
exosome-enhanced media (EEM), they formed numerous large
colonies on soft agar, whereas cells grown using exosome-free
media (EFM) showed little or no colony growth. Furthermore,
cells grown on matrigel in combination with the EEM formed
three-dimensional stellate colonies whereas cells grown with EFM
on matrigel grew mainly as a monolayer. Studies on the effects
of exosomes on cancer cell growth were reinforced by Qu et al.
(2009) who determined that exosomes derived from a gastric can-
cer cell line could promote proliferation, due in part to activation
of PI3K/AKT in the target cells.
In order for a tumor to successfully metastasize, cells must ﬁrst
extravasate from the primary tumor, intravasate into the blood or
lymph, and establish a new tumor in an environment conducive to
tumor cell growth. McCready et al. (2010) describes how invasive
cancer cells secrete exosomes containing Hsp90α, which the study
implicates in activating plasmin. The authors demonstrated that
exosomes isolated from an invasive cell line could enhance cell
migration but the effect was abrogated if an anti-Hsp90 antibody
was added in addition to the exosomes. Many proteomic changes
occur when tumor cells are induced to migrate. This is usually the
result of hypoxia, where a tumor outgrows its blood supply and
must induce migration and/or angiogenesis in order for the can-
cer cells to survive. Park et al. (2010) characterized the proteomic
changes that occurred when cells were grown in hypoxic condi-
tions and noted that 54% of the differentially regulated proteins
were co-localized with the exosome fraction of the conditioned
media. This suggests that cells undergoing hypoxic stress change
the composition of their exosomes, potentially to facilitate migra-
tion and angiogenesis. Once tumor cells have extravasated from
the primary tumor, additional conditions must bemet to establish
new tumors. Jung et al. (2009) noted that exosomes contributed
to pre-metastatic niche formation in a rat model of pancreatic
adenocarcinoma. The study noted that exosomes derived from
weakly metastatic rat ASML CD44v4–v7 knockdown cells in com-
bination with the soluble fraction of counterpart wild-type cells
caused expression changes in numerous proteases, growth factors,
and adhesion molecules. This suggests that exosomes can act over
long distances to create a metastatic environment for tumor cells.
One of the hallmarks of angiogenesis is endothelial cell activa-
tion, wherein chronic inﬂammation precedes angiogenic sprout
formation (Rajashekhar et al., 2006). It has been shown that
exosomes enriched in TSPAN8 protein are capable of activating
endothelial cells and inducing expression of many genes involved
in angiogenesis (Nazarenko et al., 2010). Furthermore, the sys-
temic role of TSPAN8-enriched exosomes in angiogenesis has
also been described. Gesierich et al. (2006) noted that rats over-
expressing D6.1A (the rat homolog of TSPAN8) suffered from
lethally disseminated intravascular coagulation. When exosomes
were isolated from isogenic cell lines, it was noted that exo-
somes from D6.1A-over-expressing cells induced endothelial cell
branching in vitro whereas the counterpart wild-type cells did
not. These effects were abrogated by the addition of an antibody
against D6.1A, but remained the same when antibodies against
other exosome-associated proteins were used. Importantly, the
authors noted high expression of D6.1A in sprouting capillaries
even if the primary tumor did not express the protein, suggest-
ing D6.1A/TSPAN8might be a therapeutic target for inhibition of
angiogenesis.
Table 1 | Summary of targets and markers isolated from cancer cell-derived exosomes.
Marker Type Exosome source Effect Reference
Amphiregulin Protein Breast, colorectal cancer Invasion Higginbotham et al. (2011)
CD44v6 Protein Rat pancreatic adenocarcinoma Pre-metastatic niche formation Jung et al. (2009)
Del-1 Protein Mesothelioma Angiogenesis* Hegmans et al. (2004), Ho et al. (2004)
EGFR Protein Pancreatic cancer, brain cancer Proliferation*, signal transduction* Adamczyk et al. (2011), Graner et al. (2009)
Hsp90α Protein Invasive carcinomas Migration, invasion McCready et al. (2010)
LMP1 Protein Nasopharyngeal carcinoma Signal transduction Meckes et al. (2010)
LRG1 Protein Non-small cell lung Signal transduction*, cell adhesion* Li et al. (2011)
MUC1 Protein Breast cancer Growth*, inhibition of Apoptosis*,
invasion*
Staubach et al. (2009)
TSPAN8 Protein Rat pancreatic adenocarcinoma Endothelial cell activation,
angiogenesis
Nazarenko et al. (2010), Gesierich et al. (2006)
Let-7 miRNA Lung cancer, metastatic gastric
cancer
Downregulate Ras* Takamizawa et al. (2004), Ohshima et al. (2010)
miR-21 miRNA Ovarian cancer, glioblastoma,
breast, pancreatic cancer
Downregulate PDCD4* Taylor and Gercel-Taylor (2008), Skog et al. (2008)
CDK8 mRNA Colorectal cancer Cell division* Hong et al. (2009)
EGFRvIII mRNA Glioblastoma Proliferation*, signal transduction* Skog et al. (2008), Graner et al. (2009)
RAD21 mRNA Colorectal cancer Mitosis*, DNA repair* Hong et al. (2009)
*Effect of marker is implied based on other published research.
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PROTEOMIC ANALYSIS OF CANCER EXOSOMES
In order to investigate the differences between tumor-derived exo-
somes and normal cell-exosomes, researchers often characterize
the proteome of tumor exosomes. Exosomes are representative
of the cell from which they were derived, so it is reasonable to
assume that proteome signatures would exhibit unique qualities
dependent on the cellular origin. Indeed, one of the ﬁrst exoso-
mal proteomes to be characterized was from mesothelioma cells.
This study identiﬁed 38 distinct proteins, many of which were
previously shown to be expressed in exosomes (Hegmans et al.,
2004). However, it is interesting to note that the authors also iden-
tiﬁed developmental endothelial locus-1 (DEL-1), a protein not
previously identiﬁed in exosomes but suggested to play a role in
angiogenesis (Ho et al., 2004).
Another study investigated the exosomal proteome of a bladder
cancer cell line. The use of exosomes in bladder cancer studies is
particularly interesting since exosomes can be isolated from urine.
The concentration of tumor-derived exosomes would theoreti-
cally be greater in a urine sample from a bladder cancer patient (in
comparison to exosomes isolated from sera of the same patient),
thus providing a potentially powerful diagnostic tool. The study
by Welton et al. (2010) identiﬁed 353 proteins contained within
HT1376-derived exosomes, 72 of which were not previously asso-
ciated with exosomes. It will be interesting to see if any of these
proteins are also found in urinary exosomes of bladder cancer
patients. To this point, a Urinary Exosome Protein Database has
been compiled based on two separate studies by the same group1.
However, in each case, fewer than 10 patients were enrolled in the
1http://dir.nhlbi.nih.gov/papers/lkem/exosome
study andall patientswerehealthy at the timeof the study (Pisitkun
et al., 2004; Gonzales et al., 2009). This database currently contains
1160 identiﬁed proteins and will undoubtedly become essential in
the identiﬁcation of urinary biomarkers of cancer patients.
Amore extensive proteomic study on urinary exosomes in can-
cer patients has been completed for non-small cell lung carcinoma
(NSCLC; Li et al., 2011). In the study, urine was collected from 10
healthy patients and 8 NSCLC patients. The proteomic differences
of the isolated exosomeswere ﬁrst characterized by 1D SDS-PAGE.
The differentially expressed proteins were then sequenced using
mass spectrometry. The authors report 18 proteins identiﬁed in
urinary exosome preparations, 11 of which were found only in
NSCLC exosomes, four only in normal exosomes, and three in
both. Of note, LRG1, a known serum cancer biomarker (Kak-
isaka et al., 2007), was identiﬁed as being highly expressed in the
NSCLC exosomes. The authors suggest that LRG1might be useful
in diagnosing NSCLC through the use of a simple urine test.
ONCOGENIC PROTEINS IN EXOSOMES
The list of proteins found in exosomes is continuously expand-
ing on ExoCarta, a database of exosomal proteins and RNA and
lipids2 (Mathivanan and Simpson, 2009). Table 2 shows several of
the top proteins found in exosomes as listed on ExoCarta. Onco-
genes that are associated with various types of cancer can often be
found in the exosomes secreted by tumor cells. Full-length EGFR
has been identiﬁed in exosomes isolated from pancreatic cell lines
(Adamczyk et al., 2011). Indeed, other studies have also identiﬁed
EGFR in exosomes originating from brain tumors (Graner et al.,
2http://www.exocarta.org
Table 2 | Proteins identified in exosomes as indicated in the ExoCarta Database.
Number Gene symbol Gene name Number of times
identified
1 CD9 CD9 molecule 46
2 HSPA8 Heat shock 70 kDa protein 8 45
3 CD63 CD63 molecule 41
4 GAPDH Glyceraldehyde-3-phosphate dehydrogenase 38
5 CD81 CD81 molecule 35
6 SDCBP Syndecan binding protein (syntenin) 32
7 PDCD6IP Programmed cell death six interacting protein 32
8 ENO1 Enolase 1, (alpha) 32
9 ANXA2 Annexin A2 32
10 ACTB Actin, beta 32
11 YWHAZ Tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein, zeta polypeptide 29
12 HSP90AA1 Heat shock protein 90 kDa alpha (cytosolic), class A member 1 29
13 ANXA5 Annexin A5 29
14 EEF1A1 eukaryotic translation elongation factor 1 alpha 1 28
15 YWHAE Tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein, epsilon polypeptide 26
16 PPIA Peptidylprolyl isomerase A (cyclophilin A) 26
17 MSN Moesin 26
18 CFL1 Coﬁlin 1 (non-muscle) 26
19 ALDOA Aldolase A, fructose-bisphosphate 26
20 PGK1 Phosphoglycerate kinase 1 25
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2009) and EGFR ligands, such as amphiregulin and TGFα, have
been identiﬁed in exosomes isolated from breast and colorectal
cell lines (Higginbotham et al., 2011). Another cell surface pro-
tein,MUC1, is commonly over-expressed in breast cancer and has
been isolated in breast cancer exosomes (Staubach et al., 2009).
However, in both cases it is not clear whether these oncogenes
retain a functional role and affect surrounding cells or if they are
simply packaged within exosomes because they are prominently
expressed in the plasma membrane.
Other studies have demonstrated not only the presence of
oncogenic proteins in exosomes, but also their ability to inﬂu-
ence cells that would receive these exosomes. Latent membrane
protein 1 (LMP1) is produced in cells infected with Epstein–Barr
virus (EBV), which is known to induce transformation in B-cell
malignancies. The LMP1protein activatesmultiple signaling path-
ways involved in apoptosis, cell cycle progression, proliferation,
and migration. Cells infected with EBV produce exosomes that
contain LMP1. Meckes et al. (2010) noted that the LMP1 con-
tained within these exosomes was capable of activating the ERK
and PI3K/AKT pathways in recipient cells. This study utilized
isogenic cell lines, both infected with EBV but only one express-
ing detectable levels of LMP1. When HUVECs were treated with
increasing amounts of exosomes from the LMP1 over-expressing
line, the amount of LMP1 protein in the recipient cells increased
in a dose-dependent manner. Exosomes isolated from the cells
without LMP1 caused an increase in phospho-ERK in recipient
HUVECs, but this increase was greater when cells were treated
with exosomes from cells that over-expressed LMP1. Therefore,
exosome-derived LMP1 can contribute to ERK and PI3K/AKT
activation in recipient cells, but it is clearly not the only effector
contained therein.
miRNA IN CANCER CELL-DERIVED EXOSOMES
microRNA are a class of small, non-coding RNA molecules that
are involved in post-transcriptional modiﬁcation of gene expres-
sion. First identiﬁed in C. elegans (Lagos-Quintana et al., 2001),
miRNA have been shown to possess oncogenic or tumor suppres-
sive properties based on how each miRNA affects gene expression
(Ahmed, 2007). In the bloodstream, miRNA have been found to
be associated with both protein complexes (Arroyo et al., 2011) as
well as microvesicles such as exosomes (Valadi et al., 2007; Kosaka
et al., 2010). These miRNA have also been referred to as “exosomal
shuttle RNA” (esRNA; Valadi et al., 2007). Exosomes offer protec-
tion from degradation by RNase enzymes (Mitchell et al., 2008),
thereby permitting miRNA manufactured in one cell to be taken
up by a neighboring cell with presumed subsequent effects on
gene expression in the target cell (Valadi et al., 2007; Kosaka et al.,
2010). Researchers have noted that certain cancer types, includ-
ing ovarian (Taylor and Gercel-Taylor, 2008), glioblastoma (Skog
et al., 2008), lung (Rosell et al., 2009), and breast (Corcoran et al.,
2011) have distinct exosomal miRNA proﬁles.
The miRNA Let-7, which was one of the ﬁrst miRNA to be
characterized, was one of several miRNA identiﬁed in exosomes
isolated from mouse mast cells (Valadi et al., 2007). Let-7 keeps
cell proliferation in check by negatively regulating Ras GTPases
(Johnson et al., 2005). Activating Ras mutations are common in
cancer, most often associated with cancers of the pancreas, colon,
lung, and also acutemyeloid leukemia (Saxena et al., 2008).A study
by Takamizawa et al. (2004) demonstrated that lower expression
of Let-7 in lung cancer patients correlated with poor survival fol-
lowing surgical resection. Interestingly, Let-7 miRNA has been
identiﬁed in exosomes isolated from a metastatic gastric cancer
cell line (Ohshima et al., 2010). The authors of the study suggest
that these cells selectively secrete let-7miRNA in order tomaintain
tumorigenic and metastatic properties.
In contrast to the tumor suppressive activities of Let-7,miRNA
have also been shown to act as oncogenes. For example, miR-
21 has been shown to be present in peripheral blood exosomes
(PBXs) isolated from patients with ovarian cancer (Taylor and
Gercel-Taylor, 2008). This particular miRNA was also present in
PBXs isolated from patients with benign ovarian disease, albeit
at ∼30% of the levels of patients with stage I, II, or III ovar-
ian cancer. It is also present at high levels in exosomes isolated
from patients with glioblastoma, though levels in healthy patients
were not determined by this particular study (Skog et al., 2008).
miR-21 abrogates expression of the antiapoptotic gene PDCD4,
thereby contributing to cell survival (Asangani et al., 2008). In
addition to being a potential marker for ovarian cancer, miR-21
is over-expressed in glioblastoma (Chan et al., 2005), breast can-
cer (Iorio et al., 2005), and pancreatic cancer (Roldo et al., 2006;
Lee et al., 2007). It has also been shown to mediate drug resis-
tance to trastuzumab in breast cancer (Gong et al., 2011) and
temozolomide in glioblastoma cells (Shi et al., 2010).
While these data regarding unique expression of miRNA in
tumor-derived exosomes is promising, these studies did not
demonstrate effects following uptake of these exosomes directly
related to the expression of a particular miRNA. Therefore, it is
not known whether these miRNA serve a functional role within
tumor exosomes. There is associative evidence that would suggest
they might mediate gene expression in target cells, but these stud-
ies are based on in vitro models where the miRNA levels might
differ greatly from those found in exosomes.
CANCER CELL-DERIVED EXOSOMAL mRNA
Exosomes are also known to containmRNA although these species
of RNA appear to be found at lower abundance compared to the
small RNA components (Zomer et al., 2010). Studies have shown
that these exosomal mRNA are functional and can be taken up
and translated by recipient cells (Ratajczak et al., 2006; Valadi
et al., 2007). Hong et al. (2009) proﬁled the mRNA of exosomes
derived from the colorectal cancer cell line SW480. The study iden-
tiﬁed over 11,000 distinct mRNA molecules within the exosome
samples. Of these, ∼2% were over-expressed at least twofold in
exosomes (compared to levels in the parental cell line). The authors
note that many of these mRNA are involved in cellular processes
such as cell division, cell cycle, and chromosome segregation. In
fact,∼11%of the over-expressedmRNA are involved in regulating
the cell cycle, speciﬁcally M-phase. When exosomes from SW480
cells were applied to HUVECs, the number of cells staining posi-
tive for a mitotic marker greatly increased. However, it is unclear
if the cell cycle mRNA contained within the applied exosomes was
the sole contributor to this resulting increase in mitosis.
Similar mRNA proﬁling was completed for exosomes derived
from clinical glioblastoma samples (Skog et al., 2008). The authors
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noted 4,700 distinct mRNA were detected only in exosome
arrays (when compared to the array of the corresponding cells
from which the exosomes were derived), suggesting a selective
enrichment process in the packaging of mRNA within exosomes.
Approximately 8% of the exosomalmRNAwere upregulatedmore
than ﬁvefold when compared to the corresponding cells. Many of
these mRNA are known to have roles in angiogenesis, cell prolifer-
ation, immune response, migration, and/or histone modiﬁcation.
Interestingly, mRNA for a mutant version of EGFR (EGFRvIII)
was identiﬁed in exosomes isolated from glioblastoma patient sera
in 7 of the 25 patients. While this is approximately half the num-
ber of actual patients whose tumors were positive for the EGFRvIII
transcript (28% positive in exosomes compared to 47% positive
in corresponding tumors), the ﬁnding that mRNA encoding a
mutant protein is present in circulating exosomes underscores the
idea that serum exosomes may provide a powerful method for
non-invasive detection of certain tumors.
EXOSOMES AS A POTENTIAL DIAGNOSTIC
The proteomic and genomic biomarkers in tumor-derived exo-
somes coupled with established methodologies for isolating exo-
somes from body ﬂuids has generated much promise in regards
to using exosomes as a diagnostic tool. In theory, a patient would
have their blood drawn using traditional methods and analysts
would isolate the circulating exosomes and screen for biomarkers
of disease. However, this raises a few questions. Would lab tests be
able to detect the relatively small percentage of tumor exosomes
in a patient’s serum? It is generally noted that tumor cells secrete
more exosomes than normal counterparts (Taylor et al., 2011), so
it is likely that tumor exosomes will be detectable. Another ques-
tion we must address is whether exosome screening can offer any
improvement over current serum biomarker tests.
The use of serum biomarkers is already established in ovar-
ian cancer, where high levels of CA125 are often indicative of a
tumor. However, the use of this marker is limited, as a signiﬁcant
portion of ovarian cancers do not express the protein. A study by
Li et al. (2009) sought to determine if diagnostic rates of ovarian
cancer could be improved using exosomes isolated from patient
plasma. They found that 51% of ovarian cancer patients (32 out of
63) had circulating exosomes that expressed the protein claudin-4,
which is often elevated in ovarian tumor cells. This is notably lower
than the sensitivity of a CA125 test on the same patient samples,
which demonstrated 71% of samples as correctly diagnosed. Both
screening methods returned a false-positive diagnosis only 2% of
the time (1 out of 50 normal patient samples).
Diagnosing malignant melanoma may also be aided by the use
of exosome screening. Logozzi et al. (2009) demonstrated that exo-
somes isolated from 69%of melanoma patients enrolled in a small
study contained caveolin-1. In contrast, only 7% of these patients
would have been correctly diagnosed using serum LDH levels, the
current-best prognostic serum factor for melanoma patients. This
suggests that diagnostic rates could be improved through the use
of a simple blood test. However, it is important that researchers
determine which biomarker(s) are most often expressed in a given
cancer type in order to prevent misdiagnosis.
One major serum-based screening method that is currently
under heated debate is the PSA test for prostate cancer screening.
This type of screen is plagued by high false-positives; when biopsy
is performed due to elevated PSA,only 25–33%of patients actually
have prostate cancer (Smith et al., 1997). One study on prostate
cancer biomarkers identiﬁed high levels of extracellular delta-
catenin in prostate cancer cells (Lu et al., 2009). Despite being
an intracellular protein, it can be isolated in urine samples. The
authors provide evidence to suggest that this is due to secretion
of prostate cancer exosomes/prostasomes, which contain delta-
catenin. Urinalysis for delta-catenin levels was completed on a
small cohort of patients and the authors noted 87.5% sensitivity
and 83.3% speciﬁcity. PSA testing on the same cohort was highly
variable. In addition, a study by Tavoosidana et al. (2011) noted
that the level of circulating prostasomes (microvesicles secreted
by prostate acinar cells) were higher in prostate cancer patients
compared to normal controls. Interestingly, higher plasma prosta-
some levels correlated with higher Gleason scores whereas PSA
levels did not correlate with Gleason scores in the same cohort.
These studies provide evidence that microvesicle-based screening
could offer marked improvements in diagnosing cancer early and
through non-invasive methods.
Several companies have begundeveloping exosome-baseddiag-
nostic tests. Exosome Diagnostics, Inc. (New York, NY, USA) has
created a bioﬂuid-based exosome test for prostate cancer, which is
currently undergoing clinical validation. Another company uti-
lizing exosomes for diagnostic purposes is Caris Life Sciences
(Irving, TX, USA). Caris Life Sciences has developed a technology
called Carisome™, where circulatory microvesicles are character-
ized to devise a biosignature, which will assist in determining
diagnosis, prognosis, and predicting patient response. In con-
trast to these companies that utilize exosomes for diagnostics,
Aethlon Medical, Inc. (San Diego, CA, USA) has developed a
product called HER2osome™, which depletes circulatory HER2
protein and tumor-related exosomes in breast cancer patients. This
type of therapy is proposed to enhance the beneﬁts of traditional
chemotherapies without adding drug toxicity or interaction risks.
EXOSOMES AS CANCER THERAPY
Because exosomes are capable of eliciting a potent immune
response, researchers have sought to determine if exosomes can
be utilized as a form of cancer immunotherapy (reviewed in
(Tan et al., 2010). Many of these studies have demonstrated the
application of dendritic cell-derived exosomes (DEX) in immune
responses against tumors in vivo. It is known that DEX can be
taken up by other dendritic cells which would likely perpetuate
and amplify the immune response. In some cases, the application
of DEX alone is not sufﬁcient to elicit an immune response against
an established tumor. Tumors are known to induce expansion of
regulatory T (Treg) cells because of the high prevalence of self-
antigens. These Treg cells are partly responsible for the tumor’s
ability to evade the immune system. However, pretreatment with
cyclophosphamide causes an elimination of the Treg cells and has
been shown to synergize with DEX, leading to a potent secondary
CD8+ T cell response and resulting in signiﬁcant tumor shrinkage
(Taieb et al., 2006).
Advances in exosome-based anti-cancer therapy have gener-
ally revolved around the application of DEX from dendritic cells
that have been pulsed with tumor antigen. But is it possible for
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exosomes derived from tumor cells to elicit a similar immune
response? Some studies have shown that this is possible, but the
tumor cells must be engineered to express certain effector proteins
(Zhang et al., 2010; Lee et al., 2011). It is unclear whether this type
of therapy is feasible, since application in a clinical setting would
have to involve removal of patient tumor cells, induction of ectopic
expression, andharvesting of exosomes. Chen et al. (2006) demon-
strated that it is possible for unmodiﬁed tumor-derived exosomes
to elicit an immune response, but the effect is more potent if the
tumor cells are heat shocked before harvesting the exosomes. This
was true in both a therapeutic and prophylaxis model. Another
study has also demonstrated the potential of tumor-derived exo-
somes as a prophylactic treatment (Bu et al., 2006), suggesting that
exosomes could be used as a true cancer vaccine.
CONCLUSION
Tumor-derived exosomes can play an important role in disease
progression and because exosomes are representative of parent
cells, tumor-derived exosomes can provide much information
about the tumor cells of origin. Studying tumor-derived exosomes
will be imperative if non-invasive, early detection methods are
to be developed. Though current detection methods are plagued
with inaccuracies, it is likely that exosome-based detection will
not be foolproof either. Cancer cells are notorious for develop-
ing mutations and changing protein expression levels in order
to increase cell survival and circumvent traditional treatments.
Therefore, it is important that exosome markers used in a cancer
detection screen be expressed almost exclusively in tumor-derived
exosomes.
Databases such as ExoCarta (Mathivanan and Simpson, 2009;
Mathivanan et al., 2012) and the Urinary Exosome Protein
Database have facilitated the sharing of data regarding the
genomics and proteomics of exosomes. As we continue to amass
this data, it will become important to determine which factors
are most relevant to exosome functions. In most of the cases pre-
sented here, the authors have noted that large-scale effects, such
as angiogenesis or cell growth, can be consequences of adding
tumor-derived exosomes to normal cells. However, these effects
are rarely due to only one protein or RNA molecule. Future exo-
some studies should focus on identiﬁcation of the “non-reducible
units” that are required for these functions. That is,which different
proteins/RNA are required to mediate these effects and are these
effects completely abrogated if the protein/RNA is not present?
Another area of interest to the ﬁeld and an area of interest to
our group is the identiﬁcation of exosomal markers that could
be used to isolate exosomes derived by speciﬁc source cells for
analysis.
The number of peer-reviewed publications focused on exo-
somes has increased exponentially within the past 15 years. Much
excitement and promise has been generated around the use of exo-
somes in disease detection. Exosomes express only a small subset
of the proteins and RNA expressed in a typical cell, which should
permit an easier understanding of how they function and interact.
These factors will hopefully expedite the clinical utilization of this
data in order to better diagnose and treat cancer patients, thereby
loweringmortality rates associatedwith such a devastating disease.
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